Posted by ABMN Staff on May 6th, 2024
AtriCure (NASDAQ:ATRC – Free Report) had its target price lowered by JPMorgan Chase & Co. from $42.00 to $34.00 in a research report report published on Thursday, Benzinga reports. The firm currently has an overweight rating...
More of this article »